Recornea Srl
Recornea is a clinical stage medtech ophthalmic company dedicated to developing innovative therapeutic solutions for eye diseases. Their mission is to enhance patients' quality of life through revolutionary, minimally-invasive bio-enhanced devices that treat ocular conditions such as keratoconus and glaucoma. They focus on coupling minimally invasive surgery with biocompatible and bio-enhanced technology, leveraging super-elastic materials like Nitinol, to create advanced ophthalmic products. Their flagship product, GROSSO® Reshaper, is the world's first nitinol intracorneal implant designed to treat keratoconus by mechanically restoring the natural corneal shape. The company is supported by various public grants and patents, and collaborates with European research entities. Recornea's vision is to prevent blindness through technological innovation.
Industries
Nr. of Employees
small (1-50)
Recornea Srl
Patents
Products
Intracorneal shape‑memory implant for keratoconus
An implantable intracorneal device made from a shape‑memory alloy designed to mechanically restore and maintain normal corneal curvature when inserted in a corneal pocket, intended to improve vision in moderate to advanced keratoconus.
Implantable filtering device for glaucoma (in development)
A filtering implant intended to create a controlled drainage pathway to manage intraocular pressure as an alternative to traditional trabeculectomy.
Intracorneal shape‑memory implant for keratoconus
An implantable intracorneal device made from a shape‑memory alloy designed to mechanically restore and maintain normal corneal curvature when inserted in a corneal pocket, intended to improve vision in moderate to advanced keratoconus.
Implantable filtering device for glaucoma (in development)
A filtering implant intended to create a controlled drainage pathway to manage intraocular pressure as an alternative to traditional trabeculectomy.
Expertise Areas
- Clinical trial management
- Regulatory compliance and quality management (ISO 13485)
- Implantable ophthalmic device design
- Biomaterials engineering (shape-memory alloys)
Key Technologies
- Nitinol (shape-memory alloy) implants
- Minimally invasive implant delivery/injector systems
- Intracorneal implant design
- Preclinical in vivo models (rabbit studies)
News & Updates
First patient treated with GROSSO® implant in clinical trial
Recornea achieved a milestone in the First In Human clinical trial for keratoconus in collaboration with IMO in Barcelona.
Regulatory approvals for clinical trial of GROSSO® Reshaper
Recornea received regulatory approval to conduct the First In Human clinical trial in Spain.
Welcoming Dr. Letizia Mansutti as Board Member
Dr. Mansutti joins as an ophthalmic surgeon, investor, and board member.
Completion of preclinical testing of GROSSO® implant
Preclinical testing stage completed, moving towards clinical trials.
Submission of clinical investigation protocol for GROSSO® implant
Protocol submitted to ethics committee and authorities for approval.
First surveillance audit of ISO 13485:2016 certification
Recornea's quality management system was audited and certified.
First patient treated with GROSSO® implant in clinical trial
Recornea achieved a milestone in the First In Human clinical trial for keratoconus in collaboration with IMO in Barcelona.
Regulatory approvals for clinical trial of GROSSO® Reshaper
Recornea received regulatory approval to conduct the First In Human clinical trial in Spain.
Welcoming Dr. Letizia Mansutti as Board Member
Dr. Mansutti joins as an ophthalmic surgeon, investor, and board member.
Completion of preclinical testing of GROSSO® implant
Preclinical testing stage completed, moving towards clinical trials.
Submission of clinical investigation protocol for GROSSO® implant
Protocol submitted to ethics committee and authorities for approval.
First surveillance audit of ISO 13485:2016 certification
Recornea's quality management system was audited and certified.